Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "Fusion"

275 News Found

Freenome strikes SPAC deal to go public in 2026
Biotech | December 08, 2025

Freenome strikes SPAC deal to go public in 2026

Freenome expects the combined company to receive approximately $330 million in proceeds at closing


B Braun unveils ready-to-use antibiotic system
R&D | December 08, 2025

B Braun unveils ready-to-use antibiotic system

DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation


Bristol Myers Squibb secures FDA nod for Breyanzi in marginal zone lymphoma
Drug Approval | December 06, 2025

Bristol Myers Squibb secures FDA nod for Breyanzi in marginal zone lymphoma

The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population


Citius Oncology's new therapy offers new hope for cutaneous T-cell lymphoma patients
News | December 03, 2025

Citius Oncology's new therapy offers new hope for cutaneous T-cell lymphoma patients

LYMPHIR addresses a clear clinical need in a disease with limited treatment options


Medtronic launches first 'intelligent' circular stapler to boost surgical precision, reduce leaks
News | November 27, 2025

Medtronic launches first 'intelligent' circular stapler to boost surgical precision, reduce leaks

The Signia Circular Stapler is the only circular stapler on the market with integrated leak testing and features designed to minimize risk


EU clears Bristol Myers Squibb’s CAR-T therapy Breyanzi for tough-to-treat Lymphoma
Drug Approval | November 25, 2025

EU clears Bristol Myers Squibb’s CAR-T therapy Breyanzi for tough-to-treat Lymphoma

The European Commission’s green light marks Breyanzi’s fourth indication in Europe and extends access to patients across all EU and EEA countries


FDA slaps gene therapy Elevidys with boxed warning after fatal liver failures
News | November 24, 2025

FDA slaps gene therapy Elevidys with boxed warning after fatal liver failures

Elevidys came under scrutiny in June when the FDA disclosed two fatal cases in non-ambulatory boys who developed dangerously high liver enzyme levels


FDA approves combo therapy for Cisplatin-ineligible muscle-invasive bladder cancer patients
Drug Approval | November 23, 2025

FDA approves combo therapy for Cisplatin-ineligible muscle-invasive bladder cancer patients

The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy